Jonathan Wessen

Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial

D. Berton, I. Vergote, S. Pignata, 2023, JCO precision oncology.

Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data.

S. Signoretti, T. Choueiri, L. Ottesen, 2022, European journal of cancer.

MET status and treatment outcomes in papillary renal cell carcinoma (PRCC): Pooled analysis of historical data.

S. Signoretti, T. Choueiri, L. Ottesen, 2020 .

Abstract 4897: Detection of MET-mediated EGFR tyrosine kinase inhibitor (TKI) resistance in advanced non-small cell lung cancer (NSCLC): biomarker analysis of the TATTON study

J. Barrett, B. Cho, Ji-Youn Han, 2019, Clinical Research (Excluding Clinical Trials).

Abstract CT032: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) withEGFR-mutant,MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)

Jie Yang, L. Sequist, B. Cho, 2019, Clinical Trials.

Abstract CT033: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) withEGFR-mutant,MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)

L. Sequist, J. Yang, B. Cho, 2019, Clinical Trials.

Abstract CT034: Osimertinib plus selumetinib for patients (pts) withEGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study

M. Ahn, Y. Ohe, H. Saka, 2019, Clinical Trials.